Results 141 to 150 of about 410,888 (293)

Charting the Course: Real‐World Application of Sustainability and Innovation Principles in the Portuguese Blue Economy Firms

Business Strategy and the Environment, EarlyView.
ABSTRACT The blue economy has emerged as a key sector for linking sustainability and innovation, yet existing research has largely overlooked how firms operationalize these processes in practice. This study addresses that gap by asking: How do Portuguese blue economy firms embed sustainability‐oriented innovation (SOI) into their strategies, and what ...
Jennifer Nicole Elston, Hugo Emanuel dos Reis Sales da Cruz Pinto, Carla Filipa Sequeira Valente Nogueira   +2 more
wiley   +1 more source

Editorial: Challenges of pharmacoeconomics in global health arena—Contemporary momentum in the early 2020s

Frontiers in Public Health, 2023
Mihajlo Jakovljevic, Mihajlo Jakovljevic, Mihajlo Jakovljevic, Nick Verhaeghe, Nick Verhaeghe, Kyriakos Souliotis, Kristijan Krstic   +6 more
doaj   +1 more source

Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study

Patient Preference and Adherence, 2018
Vera Vennedey,1 Sonja HM Derman,2 Mickaël Hiligsmann,3 Daniele Civello,1 Anja Schwalm,4 Astrid Seidl,4 Fülöp Scheibler,5 Stephanie Stock,1 Michael J Noack,2 Marion Danner1,5 1Institute for Health Economics and Clinical Epidemiology ...
Vennedey V, Derman SHM, Hiligsmann M, Civello D, Schwalm A, Seidl A, Scheibler F, Stock S, Noack MJ, Danner M   +9 more
doaj  

Impact Measuring in Sustainable Ventures: A Process Perspective

Business Strategy and the Environment, EarlyView.
ABSTRACT Impact measurement is crucial for sustainable ventures to quantify their contribution to sustainable development. Although research has highly focused on impact measurement as a static activity, we conduct a qualitative study to explore how impact measuring as a process unfolds over time.
Jan Moellmann, Esther Salvi, Frank‐Martin Belz   +2 more
wiley   +1 more source

Maine's lifelong learning accounts: good news for workers, businesses, and the economy [PDF]

Lifelong Learning Accounts (LiLAs) support current and future workforce needs. LiLA funds differ from tuition reimbursement in several ways: being available before course registration, being portable, and merging employee savings with contributions from ...
Auta Main
core  

The Role of Objective Financial Situation and Psychological Outlook in the Relationship Between Personal Life Shocks and Financial Well‐Being

Journal of Consumer Behaviour, Volume 24, Issue 2, Page 632-654, March 2025.
ABSTRACT Existing research examines the relationship between personal life shocks and financial well‐being primarily through the lens of objective markers of the individual's financial situation (e.g., liquidity). Little attention has been paid to the relative roles of these objective markers and more intuitive or affect‐based factors in how an ...
Jordan Bell, Jesse Jurgenson, Dee Warmath   +2 more
wiley   +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Pharmaceutical distribution remuneration in Europe

Journal of Pharmaceutical Policy and Practice, 2015
Sabine Vogler, Lena Lepuschütz, Peter Schneider   +2 more
doaj   +1 more source

Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. [PDF]

Regen Ther
Shi J, Hu H, Ung COL.
europepmc   +1 more source